Biotechnology

New patent expiration for Metuchen Pharms drug STENDRA – DrugPatentWatch


Copyright © DrugPatentWatch. Originally published on new patent expiration for the drug Metuchen Pharms STENDRA


Annual Drug Patent Expiration for STENDRA

Stendra is a drug marketed by Metuchen Pharms and included in one NDA. It is available from two suppliers. There are two patents protecting this drug and one Paragraph IV challenge.

STENDRA drug price trends.

Drug patent litigation for STENDRA.

This drug has fifty-three patent family members in twenty-six countries.

The generic ingredient in STENDRA is avanafil. Two registered suppliers for this compound. Additional details are available on the avanafil profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published on new patent expiration for the drug Metuchen Pharms STENDRA



Source link

Related Articles

Back to top button